Press releases
Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.
2026
27 May 2026, 07:12 | Regulatory
· The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
· Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
· Submission to EMA for conversion to full marketing authorization planned for Q4 2026
25 May 2026, 17:10
19 May 2026, 07:30 | Regulatory
· The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region
· Significantly enhances Hansa’s financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval
· SERB has a substantial European commercial presence and a successful track record in critical car…
18 May 2026, 15:35
12 May 2026, 19:15
28 Apr 2026, 08:00 | Regulatory
Lund, Sweden April 28, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gives notice to Annual General Meeting to be held on Monday June 1, 2026 at 14:30 CEST, Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund. Registration starts at 14:00 CEST.
23 Apr 2026, 07:00 | Regulatory
· PDUFA target date set for December 19 by the FDA
· Runway significantly extended
8 Apr 2026, 17:00